Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01092143




Registration number
NCT01092143
Ethics application status
Date submitted
19/03/2010
Date registered
24/03/2010
Date last updated
31/05/2022

Titles & IDs
Public title
BI 671800 ED in Steroid-naive Asthmatic Patients
Scientific title
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma
Secondary ID [1] 0 0
1268.17
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 671800
Treatment: Drugs - Fluticasone propionate placebo
Treatment: Drugs - Fluticasone propionate
Treatment: Drugs - BI 671800 Placebo

Experimental: BI 671800 (low dose) - Patients receive BI 671800 (low dose) capsules twice daily

Active comparator: Fluticasone propionate - Patients inhale from Fluticasone propionate metered dose inhaler (MDI) twice daily

Placebo comparator: Placebo - Patients receive placebo capsules twice daily

Experimental: BI 671800 (medium dose) - Patients receive BI 671800 (medium dose) capsules twice daily

Experimental: BI 671800 (high dose) - Patients receive BI 671800 (high dose) capsules twice daily


Treatment: Drugs: BI 671800
BI 671800

Treatment: Drugs: Fluticasone propionate placebo
Placebo matching Fluticasone propionate

Treatment: Drugs: Fluticasone propionate
Fluticasone propionate

Treatment: Drugs: BI 671800 Placebo
Placebo matching BI 671800
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment
Timepoint [1] 0 0
Measurements at baseline (mean observed in the 2 weeks prior to treatment) and at week 6 of treatment.
Secondary outcome [1] 0 0
Asthma Control Questionnaire (ACQ) Mean Score Change From Baseline After Six Weeks of Treatment
Timepoint [1] 0 0
Measurements at baseline (mean ACQ score obtained at Week 0) and at week 6 of treatment.

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Signed informed consent consistent with ICH-GCP
2. Three month history of reversible (12% with 200 mL) asthma (according to GINA) with following spirometry at randomization: FEV1 60%-85%.
3. No ICS previous 3 months prior to screening.
4. Diagnosis of asthma prior to 40 years.
5. ACQ at least 1.5 at randomization.
6. Male or female, 18 to 65 years.
7. Non-smokers or ex-smokers ( less than 10 pack year history) with negative cotinine screen.
8. Able to perform PFT
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Significant diseases other than asthma or allergic rhinitis.
2. Hepatic transaminases or total bilirubin greater than 1.5 ULN.
3. Hospitalizations for asthma or asthma related intubation within 3 months.
4. Uncontrolled asthma.
5. Respiratory tract infection or exacerbation within 4 weeks.
6. FEV1 less than 40%, more than 12 puffs of SABA on more than two consecutive days or asthma exacerbation during the run-in period.
7. Participation in another interventional study.
8. Pregnant or nursing women.
9. Women of child bearing potential nor using appropriate methods of birth control as defined by protocol

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/03/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/03/2011
Sample size
Target
Accrual to date
Final
389
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
1268.17.61001 Boehringer Ingelheim Investigational Site - Adelaide
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Montana
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Canada
State/province [22] 0 0
Ontario
Country [23] 0 0
Canada
State/province [23] 0 0
Quebec
Country [24] 0 0
Colombia
State/province [24] 0 0
Bogotá
Country [25] 0 0
Colombia
State/province [25] 0 0
Medellín
Country [26] 0 0
Korea, Republic of
State/province [26] 0 0
Cheongju
Country [27] 0 0
Korea, Republic of
State/province [27] 0 0
Seoul
Country [28] 0 0
Korea, Republic of
State/province [28] 0 0
Suwon
Country [29] 0 0
Korea, Republic of
State/province [29] 0 0
Wonju
Country [30] 0 0
Mexico
State/province [30] 0 0
Cuernavaca
Country [31] 0 0
Mexico
State/province [31] 0 0
Monterrey
Country [32] 0 0
Mexico
State/province [32] 0 0
Toriello Guerra
Country [33] 0 0
Mexico
State/province [33] 0 0
Zona Río
Country [34] 0 0
New Zealand
State/province [34] 0 0
Christchurch
Country [35] 0 0
New Zealand
State/province [35] 0 0
Greenlane East Auckland
Country [36] 0 0
New Zealand
State/province [36] 0 0
Newtown Wellington NZ
Country [37] 0 0
Peru
State/province [37] 0 0
Jesús María
Country [38] 0 0
Peru
State/province [38] 0 0
Lima
Country [39] 0 0
Peru
State/province [39] 0 0
San Borja
Country [40] 0 0
Peru
State/province [40] 0 0
San Isidro.
Country [41] 0 0
Peru
State/province [41] 0 0
Santiago de Surco
Country [42] 0 0
Peru
State/province [42] 0 0
Urb. Ingeniería
Country [43] 0 0
Philippines
State/province [43] 0 0
Caloocan City
Country [44] 0 0
Philippines
State/province [44] 0 0
Manila
Country [45] 0 0
Philippines
State/province [45] 0 0
Quezon City
Country [46] 0 0
Taiwan
State/province [46] 0 0
Chiayi City
Country [47] 0 0
Taiwan
State/province [47] 0 0
Kaohsiung City
Country [48] 0 0
Taiwan
State/province [48] 0 0
Taichung
Country [49] 0 0
Taiwan
State/province [49] 0 0
Taipei
Country [50] 0 0
Taiwan
State/province [50] 0 0
Taoyuan County

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01092143